ILMOFOSINE

Suppliers

Names

[ CAS No. ]:
83519-04-4

[ Name ]:
ILMOFOSINE

Chemical & Physical Properties

[ Molecular Formula ]:
C26H56NO5PS

[ Molecular Weight ]:
525.76500

[ Exact Mass ]:
525.36200

[ PSA ]:
102.93000

[ LogP ]:
7.74150

MSDS

Click to get detail MSDS

Toxicological Information

CHEMICAL IDENTIFICATION

RTECS NUMBER :
JH4758000
CHEMICAL NAME :
3,5-Dioxa-9-thia-4-phosphapentacosan-1-aminium, 4-hydroxy-7-(methoxymethyl)-N,N,N-trimethyl-, hydroxide, inner salt, 4-oxide
CAS REGISTRY NUMBER :
83519-04-4
LAST UPDATED :
199612
DATA ITEMS CITED :
7
MOLECULAR FORMULA :
C26-H56-N-O5-P-S
MOLECULAR WEIGHT :
525.86

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
253 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
74 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
615 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
113 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value

MUTATION DATA

TYPE OF TEST :
DNA inhibition
TEST SYSTEM :
Human Cells - not otherwise specified
DOSE/DURATION :
1 mg/L
REFERENCE :
CNREA8 Cancer Research. (Public Ledger Building, Suit 816, 6th & Chestnut Sts., Philadelphia, PA 19106) V.1- 1941- Volume(issue)/page/year: 43,5538,1983

Safety Information

[ Symbol ]:

GHS06

[ Signal Word ]:
Danger

[ Hazard Statements ]:
H301

[ Precautionary Statements ]:
P301 + P310

[ Personal Protective Equipment ]:
dust mask type N95 (US);Eyeshields;Faceshields;Gloves

[ Hazard Codes ]:
Xn: Harmful;

[ Risk Phrases ]:
22

[ RIDADR ]:
UN 2811 6.1/PG 3

[ RTECS ]:
JH4758000

Synthetic Route

Click to get detail synthetic route

Articles

Phase I trial of ilmofosine as a 24 hour infusion weekly.

Invest. New Drugs 13(3) , 205-10, (1995)

Ilmofosine, an ether lipid derivative of lysophosphatidylcholine has antineoplastic activity in vitro and in vivo. Maximum efficacy in preclinical models is associated with prolonged exposure to the d...

A phase II trial of ilmofosine in non-small cell bronchogenic carcinoma.

Invest. New Drugs 14(2) , 219-22, (1996)

We have conducted a study of ilmofosine (1-hexadecylthio; 2-methoxyethyl-rac-glycero-3-phosphocholine) in non-small cell bronchogenic carcinoma, using a schedule of continuous infusion for 5 days and ...

Structure-function relationships of alkyl-lysophospholipid analogs in selective antitumor activity.

Lipids 28(6) , 511-6, (1993)

This investigation was initiated in order to delineate the structure-function relationship of the anticancer alkyl-lysophospholipids and assess their degree of selective cytotoxicity toward neoplastic...


More Articles

Related Compounds

  • Ilmofosine
  • [4-(3-Methoxyphenyl)piperazin-1-yl][4-(4-methoxyphenyl)-1,2,3-thiadiazol-5-yl]methanone
  • 4-fluoro-N-[4-methoxy-3-(1H-tetrazol-1-yl)phenyl]benzamide
  • 4-{[4-(3-Chlorophenyl)-1-piperazinyl]carbonyl}-6-isopropyl-3-methylisoxazolo[5,4-b]pyridine
  • [4-(3-methoxyphenyl)piperazin-1-yl](1-methyl-1H-indol-2-yl)methanone
  • 2,2-dimethyl-N-[2-(trifluoromethyl)-1H-benzimidazol-5-yl]propanamide
  • N-[3-(dimethylamino)propyl]-2-[2-(1H-indol-3-yl)ethyl]-1,3-dioxo-2,3-dihydro-1H-isoindole-5-carboxamide
  • 1-(4-{[4-(4-Methoxyphenyl)-1,2,3-thiadiazol-5-yl]carbonyl}piperazin-1-yl)ethanone
  • 2-bromo-N-[4-methoxy-3-(1H-tetrazol-1-yl)phenyl]benzamide
  • N-[(2E)-5-(4-fluorobenzyl)-1,3,4-thiadiazol-2(3H)-ylidene]pyridine-2-carboxamide
  • 2-(3-methoxyphenyl)-N-[2-(4-sulfamoylphenyl)ethyl]quinoline-4-carboxamide
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.